Janssen Pharmaceuticals (United States) has no DMF, CEP or site registration linked in our records. 18 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Janssen Pharmaceuticals: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/janssen-pharmaceuticals

Overview

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is dedicated to addressing and solving some of the most important unmet medical needs of our time. It specializes in medicines for a variety of diseases and conditions, focusing on therapeutic areas like oncology, immunology, and neuroscience.

Core services & business areas

Biopharmaceutical ManufacturingProcess DevelopmentClinical Supply ServicesQuality Control

Therapeutic areas

FDA compliance signals

18 FDA enforcement records linked to this company.

  • 4832026-09-25

    Failure to comply with REMS Elements to Assure Safe Use (ETASU) D

  • 4832024-09-27

    Failure to comply with REMS Implementation System

  • 4832023-12-14

    Scientifically sound laboratory controls

  • 4832023-12-14

    Cleaning / Sanitizing / Maintenance

  • 4832023-12-14

    Training , Education , Experience overall

  • recall — Class II2018-11-14

    Labeling: Incorrect Instructions; Instructions included for use with the Veridate dispenser contained instructions for the Dialpak dispenser.

  • recall — Class II2018-11-14

    Labeling: Incorrect Instructions; Instructions included for use with the Veridate dispenser contained instructions for the Dialpak dispenser.

  • 4832016-09-21

    Late submission of 15-day report

  • 4832016-09-21

    Failure to develop written procedures

  • recall — Class II2015-05-20

    Subpotent Drug

  • recall — Class II2014-08-13

    Non-Sterility: Janssen is recalling one lot of Risperdal CONSTA (risperiDONE) due to a sterility failure in a stability sample

  • 4832014-02-12

    Failure to develop written procedures

  • 4832014-02-12

    Late submission of 15-day report

  • 4832011-07-21

    Failure to develop written procedures

  • warning_letter2010-09-14

    FDA Warning Letter (drug product)

  • 4832009-07-20

    Failure to develop written procedures

  • 4832009-07-20

    Failure by applicant to report ADE

  • warning_letter2008-11-24

    FDA Warning Letter (drug product)

For suppliers

Is this Janssen Pharmaceuticals?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.